GILTERITINIB SUPERIOR IN RELAPSED, REFRACTORY FLT3-MUTATED AML
For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer survival and a greater percentage of patients with remission than salvage chemotherapy, according to a study published in the Oct. 31 issue of the New England […]
GILTERITINIB SUPERIOR IN RELAPSED, REFRACTORY FLT3-MUTATED AML Read More »
